Precision Neuroscience hires two Nevro veterans for its commercial push

By Inside BCI · Edited by Velco Dar · October 18, 2026

When Nevro’s spinal cord stimulator, an implant that sends electrical pulses to the spinal cord to ease chronic pain, went on sale in the US in 2015, Katherine Neuenfeldt ran the marketing for the launch and later built the team that worked to get insurers to pay for it. On 15 October Precision Neuroscience, the New York brain implant company, announced it had hired her as senior vice president of commercial strategies and named Nevro’s founder, Konstantinos Alataris, as president.

The appointments

Neuenfeldt joined Nevro when it had about 60 employees. As vice president of market access she built a 40-person commercial team covering national accounts, pricing and contracting, analytics, patient access and reimbursement. At Precision she leads commercial strategy and market access, the work of getting insurers to cover and pay for a device. “If payers don’t cover it, patients won’t have access,” she said.

Alataris founded Nevro in 2006 and ran it until March 2011, when Michael DeMane took over as chief executive and Alataris stayed on the board. Nevro’s stimulator won a CE mark, the approval needed to sell in Europe, in 2010; FDA approval and the US launch came in 2015. Alataris joined Precision’s board in May 2025 and keeps that seat. Michael Mager, Precision’s co-founder, remains chief executive.

A new commercial set-up

Commercial work at Precision has changed hands before. In July 2024 the company hired Jayme Strauss as chief clinical and commercial officer, to build research partnerships with hospitals and drive adoption of its first commercial product. At her previous company, Viz.ai, Strauss helped win Medicare’s first new-technology add-on payment for an AI product. She is now listed as chief clinical officer.

In May 2025, alongside Alataris’s board appointment, Precision hired John Woock as chief business officer to lead commercial operations and strategy. Woock came from Axonics, a neuromodulation company Boston Scientific bought for $3.7 billion in 2024. He no longer appears on Precision’s leadership page, and the company has not announced a change. Neuenfeldt’s remit is narrower: strategy and insurance coverage.

Why it matters

Precision is hiring for insurance coverage before it has a permanent implant to sell. Its cleared device, Layer 7, is a thin film of electrodes laid on the brain’s surface, cleared through the FDA’s 510(k) route for temporary use of less than 30 days. Mager frames the next step as bringing a new Class III medical device, the FDA’s highest-risk category, to market, and Neuenfeldt names people with ALS, spinal cord injury and brainstem stroke as the patients brain-computer interfaces need to reach. Precision has said its first permanent implant will probably come in early 2028.

Approval does not settle who pays. Medicare has no dedicated coverage pathway for brain-computer interfaces, and Neuenfeldt says the evidence insurers will want has to be built now. Neuralink’s first federal lobbyists, reported in June, list coverage of brain-computer interfaces among their issues. Precision’s $250 million Series D, announced on 24 September, brought its total raised to $430 million.

Not disclosed

Precision has not said when it will file for approval of a permanent implant, what it will charge, which insurers it is talking to, or who Neuenfeldt reports to. It has not said whether Woock is still with the company, or disclosed the terms of either appointment.

What to watch

Whether Precision keeps its early-2028 target for a first permanent implant and names the FDA route it will take.

Whether it announces talks with Medicare or private insurers on coverage for brain-computer interfaces.

Whether Precision says who leads its commercial operations.

Sources

Primary:

Coverage:

Cross-reference to prior InsideBCI coverage:

market Precision-Neuroscience Konstantinos-Alataris Katherine-Neuenfeldt Michael-Mager Jayme-Strauss John-Woock Nevro spinal-cord-stimulation market-access reimbursement Medicare Layer-7 executive-appointments